CRISPR 制药

最新新闻

• 评级变动
  Morgan Stanley Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)
  TipRanks · 2026/6/11
• 评级变动
  A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $76 to $110
  \u5e02\u573a\u8d44\u8baf · 2026/5/5
• 评级变动
  Bernstein Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $56
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• 评级变动
  A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $60 to $110
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Wells Fargo Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/29
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/8/31
• 评级变动
  Morgan Stanley Upgrades CRISPR Therapeutics(CRSP.US) to Hold Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $83
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $82
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Raises Target Price to $82
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/29
• 评级变动
  Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/7/2
• 评级变动
  Evercore Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Raises Target Price to $76
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• Evercore Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $76
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• H.C. Wainwright Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。